Fornara P, Sturm W, Fabricius P G, Schmiedt E
Urologe A. 1987 May;26(3):158-61.
To recognize progression of an inoperable prostatic cancer we use clinical parameters and the prostate specific phosphatase. The prostate specific antigen (PSA) is a new, sensitive and specific laboratory tumor marker. With 363 specimens of patients without prostatic cancer we defined for the normal range of this serum parameter. In 98 men with histologically proven prostatic cancers we investigated for the clinical relevancy of the serum level of PSA. We believe, that measurement of serum PSA give important information for clinical management of prostatic cancer.
为了识别无法手术的前列腺癌的进展情况,我们使用临床参数和前列腺特异性磷酸酶。前列腺特异性抗原(PSA)是一种新的、敏感且特异的实验室肿瘤标志物。我们用363例无前列腺癌患者的标本确定了该血清参数的正常范围。在98例经组织学证实患有前列腺癌的男性中,我们研究了血清PSA水平的临床相关性。我们认为,血清PSA的检测可为前列腺癌的临床管理提供重要信息。